 WALTHAM, Mass., Oct. 05, 2021 GLOBE NEWSWIRE -- TScan Therapeutics, Inc. Nasdaq: TCRX, a biopharmaceutical company focused on the development of T-cell receptor TCR engineered T cell therapies TCR-T for the treatment of patients with cancer, today announced the appointment of Heather Savelle as Vice President, Investor Relations. Ms. Savelle brings to TScan over 20 years of experience in corporate communications and investor relations. 